Ost-müük Cyclerion Therapeutics, Inc. - CYCN CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.2612 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 0.01 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Cyclerion Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Eelmine sulgemine* | 4.2577 |
Avatud* | 4.3153 |
Aastane muutus* | 644.02% |
Päeva ulatus* | 4.2494 - 4.4057 |
52 nädala ulatus | 3.64-25.00 |
Keskmine maht (10 päeva) | 37.44K |
Keskmine maht (3 kuud) | 740.47K |
Turukapitalisatsioon | 9.47M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 2.18M |
Tulu | 914.00K |
EPS | -0.88 |
Dividendid (% kasumist) | N/A |
Beeta | 1.94 |
Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 4.2494 | -0.0264 | -0.62% | 4.2758 | 4.4729 | 4.2447 |
Jun 1, 2023 | 4.2577 | 0.0093 | 0.22% | 4.2484 | 4.2598 | 4.2473 |
May 31, 2023 | 4.2494 | 0.0016 | 0.04% | 4.2478 | 4.5128 | 4.1193 |
May 30, 2023 | 4.1304 | 0.0605 | 1.49% | 4.0699 | 4.3072 | 4.0693 |
May 26, 2023 | 3.9853 | 0.0793 | 2.03% | 3.9060 | 4.1033 | 3.9060 |
May 25, 2023 | 3.9857 | -0.1645 | -3.96% | 4.1502 | 4.2202 | 3.9052 |
May 24, 2023 | 4.2012 | 0.0892 | 2.17% | 4.1120 | 4.3759 | 4.0525 |
May 23, 2023 | 4.2498 | -0.4389 | -9.36% | 4.6887 | 4.6897 | 4.2192 |
May 22, 2023 | 4.8942 | -0.0840 | -1.69% | 4.9782 | 5.0701 | 4.8819 |
May 19, 2023 | 5.1382 | -0.2967 | -5.46% | 5.4349 | 6.4957 | 4.9816 |
May 18, 2023 | 5.8993 | 1.2525 | 26.95% | 4.6468 | 6.2522 | 4.6467 |
May 17, 2023 | 4.8927 | 0.0103 | 0.21% | 4.8824 | 5.1859 | 4.4104 |
May 16, 2023 | 5.1676 | 1.3196 | 34.29% | 3.8480 | 5.7352 | 3.6301 |
May 15, 2023 | 0.1924 | -0.0319 | -14.22% | 0.2243 | 0.2385 | 0.1745 |
May 12, 2023 | 0.2178 | -0.0555 | -20.31% | 0.2733 | 0.2734 | 0.2144 |
May 11, 2023 | 0.2674 | -0.0154 | -5.45% | 0.2828 | 0.2949 | 0.2622 |
May 10, 2023 | 0.2898 | -0.0176 | -5.73% | 0.3074 | 0.3074 | 0.2858 |
May 9, 2023 | 0.2978 | 0.0333 | 12.59% | 0.2645 | 0.3147 | 0.2645 |
May 8, 2023 | 0.2861 | 0.0091 | 3.29% | 0.2770 | 0.2861 | 0.2643 |
May 5, 2023 | 0.2758 | 0.0201 | 7.86% | 0.2557 | 0.2832 | 0.2469 |
Cyclerion Therapeutics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 1.625 | 3.942 | 2.296 | 4.507 | 0 |
Kogu tegevuskulu | 45.997 | 55.573 | 83.561 | 129.544 | 115.252 |
Müük/Üldine/admin kulud, kokku | 14.504 | 20.62 | 28.816 | 34.404 | 27.536 |
Uuringud ja arendus | 31.493 | 37.636 | 56.414 | 95.14 | 87.716 |
Tulud majandustegevusest | -44.372 | -51.631 | -81.265 | -125.037 | -115.252 |
Netotulu enne makse | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Netotulu pärast makse | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Netotulu enne erikulusid | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Netotulu | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Arvestatav tulu, v a erikulud | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Arvestatav tulu, koos erikuludega | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Jaotamisele kuuluv netotulu | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Keskmine jaotamisele kuuluv aktsia kohta | 43.469 | 39.144 | 30.403 | 27.38 | 27.4017 |
Jaotatav EPS, v a erakorralised kulud | -1.01401 | -1.31941 | -2.55902 | -4.49262 | -4.20602 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Jaotamisele kuuluv normaal-EPS | -1.01401 | -1.38795 | -2.62708 | -4.52184 | -4.20602 |
Erakorralised kulud kokku | 0 | ||||
Tulu | 1.625 | 3.942 | 2.296 | 4.507 | |
Intressitulud (kulu), muud tulud, neto | 0.294 | -0.016 | 0.588 | 2.029 | |
Ootamatud kulutused (tulu) | 0 | -2.683 | -1.669 | ||
Muud, neto | 0 | 2.875 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0.608 | 0 | 0.306 | 0.711 |
Tulu | 0 | 0.608 | 0 | 0.306 | 0.711 |
Kogu tegevuskulu | 7.042 | 7.956 | 10.607 | 13.739 | 13.695 |
Müük/Üldine/admin kulud, kokku | 3.269 | 3.506 | 3.525 | 3.521 | 3.952 |
Uuringud ja arendus | 3.773 | 4.45 | 7.082 | 10.218 | 9.743 |
Ootamatud kulutused (tulu) | 0 | 0 | 0 | ||
Tulud majandustegevusest | -7.042 | -7.348 | -10.607 | -13.433 | -12.984 |
Intressitulud (kulu), muud tulud, neto | 0.088 | 0.132 | 0.111 | 0.045 | 0.006 |
Netotulu enne makse | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Netotulu pärast makse | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Netotulu enne erikulusid | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Netotulu | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Arvestatav tulu, v a erikulud | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Arvestatav tulu, koos erikuludega | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Jaotamisele kuuluv netotulu | -6.954 | -7.216 | -10.496 | -13.388 | -12.978 |
Keskmine jaotamisele kuuluv aktsia kohta | 43.521 | 43.505 | 43.488 | 43.459 | 43.425 |
Jaotatav EPS, v a erakorralised kulud | -0.15978 | -0.16587 | -0.24135 | -0.30806 | -0.29886 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.15978 | -0.16587 | -0.24135 | -0.30806 | -0.29886 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 14.82 | 55.457 | 58.501 | 101.197 | 0.879 |
Prepaid Expenses | 0.805 | 0.928 | 0.816 | 1.966 | 0.867 |
Other Current Assets, Total | 0.537 | 0.468 | 3.163 | 2.862 | 0.012 |
Total Assets | 18.079 | 59.331 | 115.378 | 186.478 | 7.401 |
Property/Plant/Equipment, Total - Net | 1.218 | 1.467 | 50.267 | 79.75 | 6.497 |
Property/Plant/Equipment, Total - Gross | 3.399 | 3.667 | 60.554 | 101.352 | 21.988 |
Accumulated Depreciation, Total | -2.181 | -2.2 | -10.287 | -21.602 | -15.491 |
Other Long Term Assets, Total | 2.041 | 2.407 | 6.61 | 5.531 | 0.025 |
Total Current Liabilities | 7.627 | 11.085 | 16.952 | 18.249 | 17.846 |
Accounts Payable | 2.97 | 1.828 | 1.435 | 3.311 | 2.781 |
Accrued Expenses | 4.589 | 8.759 | 11.832 | 14.534 | 14.295 |
Notes Payable/Short Term Debt | 0 | 0 | 3.509 | 0 | 0 |
Other Current Liabilities, Total | 0.068 | 0.498 | 0.176 | 0.404 | 0.77 |
Total Liabilities | 7.627 | 11.085 | 55.885 | 88.749 | 17.846 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 10.452 | 48.246 | 59.493 | 97.729 | -10.445 |
Other Equity, Total | -0.02 | -0.023 | -0.027 | -0.02 | -10.445 |
Total Liabilities & Shareholders’ Equity | 18.079 | 59.331 | 115.378 | 186.478 | 7.401 |
Total Common Shares Outstanding | 43.5187 | 43.4102 | 34.0473 | 27.5981 | 27.4017 |
Raha ja lühiajalised investeeringud | 13.382 | 53.961 | 54.395 | 94.895 | |
Raha ja ekvivalendid | 13.382 | 53.961 | 54.395 | 94.895 | |
Laekumata arved, neto | 0.096 | 0.1 | 0.127 | 1.474 | |
Accounts Receivable - Trade, Net | 0.096 | 0.1 | 0.127 | 1.474 | |
Other Liabilities, Total | 0 | 0 | 38.933 | 70.5 | |
Common Stock | 0 | 0 | 0 | 0 | |
Additional Paid-In Capital | 269.626 | 263.345 | 222.949 | 183.376 | |
Retained Earnings (Accumulated Deficit) | -259.154 | -215.076 | -163.429 | -85.627 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 8.335 | 14.82 | 21.656 | 31.679 | 42.836 |
Raha ja lühiajalised investeeringud | 7.169 | 13.382 | 20.405 | 30.323 | 41.125 |
Raha ja ekvivalendid | 7.169 | 13.382 | 20.405 | 30.323 | 41.125 |
Laekumata arved, neto | 0.096 | 0.096 | 0.227 | 0.227 | 0.227 |
Accounts Receivable - Trade, Net | 0.096 | 0.096 | 0.227 | 0.227 | 0.227 |
Prepaid Expenses | 0.567 | 0.805 | 0.536 | 0.647 | 1.007 |
Other Current Assets, Total | 0.503 | 0.537 | 0.488 | 0.482 | 0.477 |
Total Assets | 11.456 | 18.079 | 25.053 | 35.213 | 46.525 |
Property/Plant/Equipment, Total - Net | 1.171 | 1.218 | 1.264 | 1.31 | 1.373 |
Property/Plant/Equipment, Total - Gross | 3.345 | 3.399 | 3.529 | 3.575 | 3.621 |
Accumulated Depreciation, Total | -2.174 | -2.181 | -2.265 | -2.265 | -2.248 |
Other Long Term Assets, Total | 1.95 | 2.041 | 2.133 | 2.224 | 2.316 |
Total Current Liabilities | 7.531 | 7.627 | 8.529 | 9.852 | 9.491 |
Accounts Payable | 3.925 | 2.97 | 1.645 | 2.767 | 2.519 |
Accrued Expenses | 3.466 | 4.589 | 6.725 | 6.89 | 6.586 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.14 | 0.068 | 0.159 | 0.195 | 0.386 |
Total Liabilities | 7.531 | 7.627 | 8.529 | 9.852 | 9.491 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0 | 0 | 0 | 0 |
Total Equity | 3.925 | 10.452 | 16.524 | 25.361 | 37.034 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 270.052 | 269.626 | 268.49 | 266.828 | 265.112 |
Retained Earnings (Accumulated Deficit) | -266.108 | -259.154 | -251.938 | -241.442 | -228.054 |
Other Equity, Total | -0.019 | -0.02 | -0.028 | -0.025 | -0.024 |
Total Liabilities & Shareholders’ Equity | 11.456 | 18.079 | 25.053 | 35.213 | 46.525 |
Total Common Shares Outstanding | 43.5249 | 43.5187 | 43.4942 | 43.4798 | 43.4484 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -44.078 | -51.647 | -77.802 | -123.008 | -115.252 |
Raha majandustegevusest | -40.611 | -36.517 | -72.49 | -102.215 | -97.503 |
Raha majandustegevusest | 0.065 | 0.472 | 2.297 | 2.7 | 1.528 |
Mittelikviidsed varad | 6.252 | 13.25 | 10.607 | 20.382 | 12.433 |
Muutused tööjõus | -2.85 | 1.408 | -7.592 | -2.289 | 3.788 |
Tulu investeeringutelt | 0 | 1.457 | 0.018 | -6.715 | -3.438 |
Kapitalikulutused | 0 | -0.007 | -1.524 | -6.888 | -3.438 |
Rahavood investeeringutelt | 0.029 | 30.785 | 28.09 | 211.571 | 100.941 |
Rahavoogudesse investeerimine | 36.061 | 100.941 | |||
Rahaline kogumuutus | -40.579 | -4.271 | -44.389 | 102.621 | 0 |
Muud rahavood investeeringutelt, kokku | 0 | 1.464 | 1.542 | 0.173 | |
Aktsiate emiteerimine (tagasiost), neto | 0.029 | 30.785 | 24.581 | 175.51 | |
Muutused valuutakursside kõikumisest | 0.003 | 0.004 | -0.007 | -0.02 | |
Laenu väljastamine (kustutamine), neto | 0 | 3.509 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -6.954 | -44.078 | -36.862 | -26.366 | -12.978 |
Cash From Operating Activities | -6.214 | -40.611 | -33.568 | -23.653 | -12.835 |
Cash From Operating Activities | 0 | 0.065 | 0.065 | 0.065 | 0.048 |
Non-Cash Items | 0.426 | 6.252 | 5.128 | 3.466 | 1.767 |
Changes in Working Capital | 0.314 | -2.85 | -1.899 | -0.818 | -1.672 |
Cash From Investing Activities | 0 | 0 | 0 | 0 | |
Capital Expenditures | 0 | 0 | |||
Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
Cash From Financing Activities | 0.029 | 0.017 | 0.017 | 0 | |
Issuance (Retirement) of Stock, Net | 0.029 | 0.017 | 0.017 | 0 | |
Net Change in Cash | -6.213 | -40.579 | -33.556 | -23.638 | -12.836 |
Issuance (Retirement) of Debt, Net | |||||
Foreign Exchange Effects | 0.001 | 0.003 | -0.005 | -0.002 | -0.001 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Slate Path Capital LP | Investment Advisor | 16.4448 | 357880 | 0 | 2023-03-31 | MED |
Hecht (Peter M) | Individual Investor | 15.0436 | 327385 | 225000 | 2023-05-19 | MED |
Fidelity Management & Research Company LLC | Investment Advisor | 7.7895 | 169518 | -1530 | 2023-03-31 | LOW |
MFN Partners Management LP | Hedge Fund | 7.7869 | 169461 | 0 | 2023-03-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 6.3597 | 138403 | 0 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7945 | 82577 | 0 | 2023-03-31 | LOW |
Polaris Venture Partners | Venture Capital | 1.6598 | 36122 | 0 | 2023-02-28 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3607 | 29612 | 275 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.8271 | 18000 | -15 | 2023-03-31 | LOW |
Trustcore Financial Services, LLC | Investment Advisor | 0.6724 | 14632 | 0 | 2022-12-31 | LOW |
CAPTRUST Financial Advisors | Investment Advisor | 0.6724 | 14632 | 14632 | 2023-03-31 | LOW |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5329 | 11598 | 0 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2652 | 5771 | 0 | 2023-03-31 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2642 | 5750 | 0 | 2023-03-31 | LOW |
The Colony Group, LLC | Investment Advisor | 0.2364 | 5144 | 0 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.1992 | 4335 | -4844 | 2023-03-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1855 | 4037 | 0 | 2023-03-31 | LOW |
Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 0.1813 | 3946 | 0 | 2023-03-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.1038 | 2259 | 1306 | 2023-03-31 | MED |
Intrinsic Value Partners, LLC | Investment Advisor | 0.099 | 2155 | -6 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cyclerion Therapeutics, Inc. Company profile
Ettevõttest Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõtte juhtiv ravim CY6463 on kesknärvisüsteemi (KNS) läbiv, lahustuv guanülaatsüklaasi (sGC) stimulaator, mis on kliinilises arenduses Alzheimeri tõve koos vaskulaarse patoloogiaga (ADv), skisofreeniaga seotud kognitiivsete häirete (CIAS) ja mitokondriaalse entsefalomüopaatia, laktatsidoosi ja insuldilaadsete episoodide (MELAS) raviks. CY6463 on suukaudselt manustatav kesknärvisüsteemi läbipõletav sGC-stimulaator, mida arendatakse sümptomaatilise ja haigust modifitseeriva ravina raskete kesknärvisüsteemi haiguste puhul. CY3018 on diferentseeritud kesknärvisüsteemi läbitungiv sGC-stimulaator, millel on CY6463-ga võrreldes CSF-plasma ekspositsioon. CY3018 keskendub sGC stimuleerimisele kesknärvisüsteemi haiguste raviks. Tema mitte-tsNS varade hulka kuuluvad Praliciguat ja Olinciguat. Praliciguat on suukaudselt manustatav, üks kord päevas manustatav süsteemne sGC-stimulaator. Olinciguat on suukaudselt manustatav, üks kord päevas manustatav vaskulaarne sGC-stimulaator.
Industry: | Biotechnology & Medical Research (NEC) |
155 Federal Street, Suite 700
BOSTON
MASSACHUSETTS 02110-1727
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com